MiNK Therapeutics (INKT) News Today

MiNK Therapeutics, Inc. (NASDAQ:INKT) shares have moved lower as analysts delivered a mix of fresh ratings and earnings-estimate revisions. Below is a breakdown of the key developments:

• Positive Sentiment: B. Riley raised its FY2028 EPS forecast to $5.00 per share from a prior estimate of ($5.18). Free Report
• Neutral Sentiment: B. Riley reaffirmed its “Strong-Buy” rating on the stock. MarketBeat INKT
• Negative Sentiment: Zacks Research downgraded INKT from a “Hold” to a “Strong Sell” rating. Rating Downgrade
• Negative Sentiment: INKT was added to the Zacks Rank #5 (Strong Sell) list on August 22. Zacks Rank List
• Negative Sentiment: B. Riley cut EPS forecasts across several periods: Q3 2025 to ($0.91) from ($0.71), Q4 2025 to ($0.96) from ($0.79), FY2025 to ($3.58) from ($2.90), FY2026 to ($4.17) from ($3.43), FY2027 to ($4.63) from ($3.85) and FY2029 to ($5.43) from ($3.21). Free Report